Overview

A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia
Phase:
PHASE4
Details
Lead Sponsor:
Myungmoon Pharma. Co. Ltd.
Treatments:
1-(2-chloroethyl)-1-nitrosourea